Increased fibroblast growth factor-21 in chronic kidney disease is a trade-off between survival benefit and blood pressure dysregulation.
Nakano T, Shiizaki K, Miura Y, Matsui M, Kosaki K, Mori S, Yamagata K, Maeda S, Kishi T, Usui N, Yoshida M, Onaka T, Mizukami H, Kaneda R, Karasawa K, Nitta K, Kurosu H, Kuro-O M.
Nakano T, et al. Among authors: yamagata k.
Sci Rep. 2019 Dec 17;9(1):19247. doi: 10.1038/s41598-019-55643-4.
Sci Rep. 2019.
PMID: 31848393
Free PMC article.